{
    "organizations": [],
    "uuid": "5d55a3a29a343b489e4ff8a0e374bff3ab5834c9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sanofi-pasteur-strucks-licence-agr/brief-sanofi-pasteur-strucks-licence-agreement-with-sk-chemicals-idUSFWN1Q20OJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Sanofi Pasteur strucks licence agreement with SK Chemicals",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 12 (Reuters) - Sanofi:\n* SK Chemicals announces license agreement with Sanofi Pasteur in cell culture technology for potential use in Sanofiâ€™s strategic broadly protective influenza vaccine development program\n* agreement between SK Chemicals and Sanofi Pasteur is eligible for payment of up to $155 million when achieving all milestones Further company coverage:\n ",
    "published": "2018-02-12T19:41:00.000+02:00",
    "crawled": "2018-02-13T15:47:53.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "sanofi",
        "sk",
        "chemical",
        "announces",
        "license",
        "agreement",
        "sanofi",
        "pasteur",
        "cell",
        "culture",
        "technology",
        "potential",
        "use",
        "sanofi",
        "strategic",
        "broadly",
        "protective",
        "influenza",
        "vaccine",
        "development",
        "program",
        "agreement",
        "sk",
        "chemical",
        "sanofi",
        "pasteur",
        "eligible",
        "payment",
        "million",
        "achieving",
        "milestone",
        "company",
        "coverage"
    ]
}